CYC Stock Overview
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Cyclopharm Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$1.77 |
52 Week High | AU$2.87 |
52 Week Low | AU$1.37 |
Beta | 0.78 |
11 Month Change | 26.88% |
3 Month Change | -3.54% |
1 Year Change | -7.81% |
33 Year Change | 8.92% |
5 Year Change | n/a |
Change since IPO | 96.67% |
Recent News & Updates
Recent updates
Shareholder Returns
CYC | AU Medical Equipment | AU Market | |
---|---|---|---|
7D | 17.2% | -0.8% | 0.2% |
1Y | -7.8% | 25.4% | 8.9% |
Return vs Industry: CYC underperformed the Australian Medical Equipment industry which returned 27.9% over the past year.
Return vs Market: CYC underperformed the Australian Market which returned 10.7% over the past year.
Price Volatility
CYC volatility | |
---|---|
CYC Average Weekly Movement | 9.0% |
Medical Equipment Industry Average Movement | 9.2% |
Market Average Movement | 8.3% |
10% most volatile stocks in AU Market | 16.3% |
10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: CYC has not had significant price volatility in the past 3 months.
Volatility Over Time: CYC's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1986 | 87 | James McBrayer | www.cyclopharm.com |
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism.
Cyclopharm Limited Fundamentals Summary
CYC fundamental statistics | |
---|---|
Market cap | AU$174.86m |
Earnings (TTM) | -AU$4.70m |
Revenue (TTM) | AU$27.14m |
7.1x
P/S Ratio-41.2x
P/E RatioIs CYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CYC income statement (TTM) | |
---|---|
Revenue | AU$27.14m |
Cost of Revenue | AU$10.26m |
Gross Profit | AU$16.88m |
Other Expenses | AU$21.58m |
Earnings | -AU$4.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.043 |
Gross Margin | 62.21% |
Net Profit Margin | -17.32% |
Debt/Equity Ratio | 0% |
How did CYC perform over the long term?
See historical performance and comparison